After a life-changing cancer diagnosis, one nurse is prioritizing faith over fear while navigating the complexities of metastatic triple-negative breast cancer. Vanessa, a travel nurse from Memphis, Tennessee, had her plans derailed when she was diagnosed with stage 3 triple-negative breast cancer, the most aggressive subtype. Despite her medical background, she found herself in unfamiliar territory.
“I’ve taken care of patients my whole life,” she says. “But I didn’t really know what breast cancer truly entailed.”
Treatment began swiftly, but the cancer eventually spread, leading to a metastatic diagnosis. “When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,” she recalls.
Triple-negative breast cancer grows and spreads more quickly than many other types, and for about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to keep the cancer from growing. This makes selecting the right treatment from day one critical. The disease also disproportionately affects younger women and Black and Hispanic women, making access to education and advanced treatments a matter of survival for these communities.
Historically, metastatic triple-negative breast cancer treatment options were limited to chemotherapy, which affects all rapidly dividing cells. However, a newer class of medicines called antibody-drug conjugates (ADCs) offers a more targeted approach. ADCs are designed to bind to specific markers on cancer cells and deliver chemotherapy directly to them, potentially sparing healthy cells.
Until recently, ADCs were used later in treatment, but now they may be given as the first treatment after a metastatic diagnosis. Innovations like ADCs have already helped many patients by keeping cancer from growing, allowing them to plan their lives better, as Vanessa has experienced.
Dr. Gregory Vidal, Vanessa’s medical oncologist, emphasizes that not all ADCs are the same and that safety and efficacy vary. “When selecting treatment, it’s important to consider patients’ goals, wishes and needs so that we can try to realistically plan around those,” he says. “All patients are different and may qualify for different ADCs.”
He encourages patients to have open conversations with their care team and ask questions about treatment goals. Every patient’s experience is unique, but many with metastatic breast cancer remain on treatment for life, aiming to manage the disease and maintain quality of life.
Vanessa leaned on friends and family to keep “faith over fear,” focusing on positives and planning outings around treatments. She urges others to stay positive, ask questions, and advocate for themselves. “You definitely have a fight in front of you, but you can get through this,” she says. “You have to do your research and get answers.”
For more information on navigating ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.
